AustralieFrV1, PascalFrancis, Curation, bibRecord, 002732

Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria

Identifieur interne : 002732 ( PascalFrancis/Curation ); précédent : 002731; suivant : 002733

Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria

Auteurs : Oliver T. Mytton [Thaïlande, Royaume-Uni, Australie, France] ; Elizabeth A. Ashley ; Leon Peto ; Ric N. Price ; Yar La ; Rae Hae ; Pratap Singhasivanon ; Nicholas J. White ; Francois Nosten

Source :

The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2007.

RBID : Pascal:07-0457237

Descripteurs français

Pascal (Inist)
- Electrocardiographie, Artémisinine, Paludisme, Toxicité, Coeur, Evaluation, Traitement, Plasmodium falciparum, Médecine tropicale, Association médicamenteuse, Homme, Chimiothérapie, Thaïlande, Antiparasitaire, Antipaludique, Pipéraquine.
Wicri :
- geographic : Thaïlande.
- topic : Homme.

English descriptors

KwdEn :
- Antimalarial, Artemisinin, Chemotherapy, Drug combination, Electrocardiography, Evaluation, Heart, Human, Malaria, Parasiticide, Piperaquine, Plasmodium falciparum, Thailand, Toxicity, Treatment, Tropical medicine.

Abstract

Dihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.

A01	`01`	`1`		`@0 0002-9637`
A02	`01`			`@0 AJTHAB`
A03		`1`		`@0 Am. j. trop. med. hyg.`
A05				`@2 77`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria`
A11	`01`	`1`		`@1 MYTTON (Oliver T.)`
A11	`02`	`1`		`@1 ASHLEY (Elizabeth A.)`
A11	`03`	`1`		`@1 PETO (Leon)`
A11	`04`	`1`		`@1 PRICE (Ric N.)`
A11	`05`	`1`		`@1 LA (Yar)`
A11	`06`	`1`		`@1 HAE (Rae)`
A11	`07`	`1`		`@1 SINGHASIVANON (Pratap)`
A11	`08`	`1`		`@1 WHITE (Nicholas J.)`
A11	`09`	`1`		`@1 NOSTEN (Francois)`
A14	`01`			`@1 Shoklo Malaria Research Unit @2 Mae Sot @3 THA`
A14	`02`			`@1 Faculty of Tropical Medicine, Mahidol University @2 Bangkok @3 THA`
A14	`03`			`@1 Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road @2 Headington, Oxford @3 GBR`
A14	`04`			`@1 Menzies School of Health Research, Charles Darwin University @2 Darwin @3 AUS`
A14	`05`			`@1 Epicentre @2 Paris @3 FRA`
A20				`@1 447-450`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6817 @5 354000162434390080`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 07-0457237`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 The American journal of tropical medicine and hygiene`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.
C02	`01`	`X`		`@0 002B05E02B4`
C03	`01`	`X`	`FRE`	`@0 Electrocardiographie @5 01`
C03	`01`	`X`	`ENG`	`@0 Electrocardiography @5 01`
C03	`01`	`X`	`SPA`	`@0 Electrocardiografía @5 01`
C03	`02`	`X`	`FRE`	`@0 Artémisinine @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Artemisinin @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Artemisinina @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Paludisme @5 03`
C03	`03`	`X`	`ENG`	`@0 Malaria @5 03`
C03	`03`	`X`	`SPA`	`@0 Paludismo @5 03`
C03	`04`	`X`	`FRE`	`@0 Toxicité @5 09`
C03	`04`	`X`	`ENG`	`@0 Toxicity @5 09`
C03	`04`	`X`	`SPA`	`@0 Toxicidad @5 09`
C03	`05`	`X`	`FRE`	`@0 Coeur @5 10`
C03	`05`	`X`	`ENG`	`@0 Heart @5 10`
C03	`05`	`X`	`SPA`	`@0 Corazón @5 10`
C03	`06`	`X`	`FRE`	`@0 Evaluation @5 11`
C03	`06`	`X`	`ENG`	`@0 Evaluation @5 11`
C03	`06`	`X`	`SPA`	`@0 Evaluación @5 11`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 12`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 12`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 12`
C03	`08`	`X`	`FRE`	`@0 Plasmodium falciparum @2 NS @5 13`
C03	`08`	`X`	`ENG`	`@0 Plasmodium falciparum @2 NS @5 13`
C03	`08`	`X`	`SPA`	`@0 Plasmodium falciparum @2 NS @5 13`
C03	`09`	`X`	`FRE`	`@0 Médecine tropicale @5 14`
C03	`09`	`X`	`ENG`	`@0 Tropical medicine @5 14`
C03	`09`	`X`	`SPA`	`@0 Medicina tropical @5 14`
C03	`10`	`X`	`FRE`	`@0 Association médicamenteuse @5 15`
C03	`10`	`X`	`ENG`	`@0 Drug combination @5 15`
C03	`10`	`X`	`SPA`	`@0 Asociación medicamentosa @5 15`
C03	`11`	`X`	`FRE`	`@0 Homme @5 16`
C03	`11`	`X`	`ENG`	`@0 Human @5 16`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 16`
C03	`12`	`X`	`FRE`	`@0 Chimiothérapie @5 17`
C03	`12`	`X`	`ENG`	`@0 Chemotherapy @5 17`
C03	`12`	`X`	`SPA`	`@0 Quimioterapia @5 17`
C03	`13`	`X`	`FRE`	`@0 Thaïlande @2 NG @5 18`
C03	`13`	`X`	`ENG`	`@0 Thailand @2 NG @5 18`
C03	`13`	`X`	`SPA`	`@0 Tailandia @2 NG @5 18`
C03	`14`	`X`	`FRE`	`@0 Antiparasitaire @5 25`
C03	`14`	`X`	`ENG`	`@0 Parasiticide @5 25`
C03	`14`	`X`	`SPA`	`@0 Antiparasitario @5 25`
C03	`15`	`X`	`FRE`	`@0 Antipaludique @5 26`
C03	`15`	`X`	`ENG`	`@0 Antimalarial @5 26`
C03	`15`	`X`	`SPA`	`@0 Antipalúdico @5 26`
C03	`16`	`X`	`FRE`	`@0 Pipéraquine @4 CD @5 96`
C03	`16`	`X`	`ENG`	`@0 Piperaquine @4 CD @5 96`
C03	`16`	`X`	`SPA`	`@0 Piperaquina @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Protozoose`
C07	`01`	`X`	`ENG`	`@0 Protozoal disease`
C07	`01`	`X`	`SPA`	`@0 Protozoosis`
C07	`02`	`X`	`FRE`	`@0 Parasitose`
C07	`02`	`X`	`ENG`	`@0 Parasitosis`
C07	`02`	`X`	`SPA`	`@0 Parasitosis`
C07	`03`	`X`	`FRE`	`@0 Infection`
C07	`03`	`X`	`ENG`	`@0 Infection`
C07	`03`	`X`	`SPA`	`@0 Infección`
C07	`04`	`X`	`FRE`	`@0 Apicomplexa @2 NS`
C07	`04`	`X`	`ENG`	`@0 Apicomplexa @2 NS`
C07	`04`	`X`	`SPA`	`@0 Apicomplexa @2 NS`
C07	`05`	`X`	`FRE`	`@0 Protozoa @2 NS`
C07	`05`	`X`	`ENG`	`@0 Protozoa @2 NS`
C07	`05`	`X`	`SPA`	`@0 Protozoa @2 NS`
C07	`06`	`X`	`FRE`	`@0 Asie @2 NG`
C07	`06`	`X`	`ENG`	`@0 Asia @2 NG`
C07	`06`	`X`	`SPA`	`@0 Asia @2 NG`
C07	`07`	`X`	`FRE`	`@0 Electrodiagnostic @5 37`
C07	`07`	`X`	`ENG`	`@0 Electrodiagnosis @5 37`
C07	`07`	`X`	`SPA`	`@0 Electrodiagnóstico @5 37`
C07	`08`	`X`	`FRE`	`@0 Quinoléine dérivé @2 FF @5 38`
C07	`08`	`X`	`ENG`	`@0 Quinoline derivatives @2 FF @5 38`
C07	`08`	`X`	`SPA`	`@0 Quinolina derivado @2 FF @5 38`
N21				`@1 302`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003956

Links to Exploration step

Pascal:07-0457237

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria</title>
<author><name sortKey="Mytton, Oliver T" sort="Mytton, Oliver T" uniqKey="Mytton O" first="Oliver T." last="Mytton">Oliver T. Mytton</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Shoklo Malaria Research Unit</s1>
<s2>Mae Sot</s2>
<s3>THA</s3>
</inist:fA14>
<country>Thaïlande</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Tropical Medicine, Mahidol University</s1>
<s2>Bangkok</s2>
<s3>THA</s3>
</inist:fA14>
<country>Thaïlande</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road</s1>
<s2>Headington, Oxford</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Menzies School of Health Research, Charles Darwin University</s1>
<s2>Darwin</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Epicentre</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ashley, Elizabeth A" sort="Ashley, Elizabeth A" uniqKey="Ashley E" first="Elizabeth A." last="Ashley">Elizabeth A. Ashley</name>
</author>
<author><name sortKey="Peto, Leon" sort="Peto, Leon" uniqKey="Peto L" first="Leon" last="Peto">Leon Peto</name>
</author>
<author><name sortKey="Price, Ric N" sort="Price, Ric N" uniqKey="Price R" first="Ric N." last="Price">Ric N. Price</name>
</author>
<author><name sortKey="La, Yar" sort="La, Yar" uniqKey="La Y" first="Yar" last="La">Yar La</name>
</author>
<author><name sortKey="Hae, Rae" sort="Hae, Rae" uniqKey="Hae R" first="Rae" last="Hae">Rae Hae</name>
</author>
<author><name sortKey="Singhasivanon, Pratap" sort="Singhasivanon, Pratap" uniqKey="Singhasivanon P" first="Pratap" last="Singhasivanon">Pratap Singhasivanon</name>
</author>
<author><name sortKey="White, Nicholas J" sort="White, Nicholas J" uniqKey="White N" first="Nicholas J." last="White">Nicholas J. White</name>
</author>
<author><name sortKey="Nosten, Francois" sort="Nosten, Francois" uniqKey="Nosten F" first="Francois" last="Nosten">Francois Nosten</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0457237</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0457237 INIST</idno>
<idno type="RBID">Pascal:07-0457237</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003956</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002732</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria</title>
<author><name sortKey="Mytton, Oliver T" sort="Mytton, Oliver T" uniqKey="Mytton O" first="Oliver T." last="Mytton">Oliver T. Mytton</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Shoklo Malaria Research Unit</s1>
<s2>Mae Sot</s2>
<s3>THA</s3>
</inist:fA14>
<country>Thaïlande</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Tropical Medicine, Mahidol University</s1>
<s2>Bangkok</s2>
<s3>THA</s3>
</inist:fA14>
<country>Thaïlande</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road</s1>
<s2>Headington, Oxford</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Menzies School of Health Research, Charles Darwin University</s1>
<s2>Darwin</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Epicentre</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ashley, Elizabeth A" sort="Ashley, Elizabeth A" uniqKey="Ashley E" first="Elizabeth A." last="Ashley">Elizabeth A. Ashley</name>
</author>
<author><name sortKey="Peto, Leon" sort="Peto, Leon" uniqKey="Peto L" first="Leon" last="Peto">Leon Peto</name>
</author>
<author><name sortKey="Price, Ric N" sort="Price, Ric N" uniqKey="Price R" first="Ric N." last="Price">Ric N. Price</name>
</author>
<author><name sortKey="La, Yar" sort="La, Yar" uniqKey="La Y" first="Yar" last="La">Yar La</name>
</author>
<author><name sortKey="Hae, Rae" sort="Hae, Rae" uniqKey="Hae R" first="Rae" last="Hae">Rae Hae</name>
</author>
<author><name sortKey="Singhasivanon, Pratap" sort="Singhasivanon, Pratap" uniqKey="Singhasivanon P" first="Pratap" last="Singhasivanon">Pratap Singhasivanon</name>
</author>
<author><name sortKey="White, Nicholas J" sort="White, Nicholas J" uniqKey="White N" first="Nicholas J." last="White">Nicholas J. White</name>
</author>
<author><name sortKey="Nosten, Francois" sort="Nosten, Francois" uniqKey="Nosten F" first="Francois" last="Nosten">Francois Nosten</name>
</author>
</analytic>
<series><title level="j" type="main">The American journal of tropical medicine and hygiene</title>
<title level="j" type="abbreviated">Am. j. trop. med. hyg.</title>
<idno type="ISSN">0002-9637</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The American journal of tropical medicine and hygiene</title>
<title level="j" type="abbreviated">Am. j. trop. med. hyg.</title>
<idno type="ISSN">0002-9637</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarial</term>
<term>Artemisinin</term>
<term>Chemotherapy</term>
<term>Drug combination</term>
<term>Electrocardiography</term>
<term>Evaluation</term>
<term>Heart</term>
<term>Human</term>
<term>Malaria</term>
<term>Parasiticide</term>
<term>Piperaquine</term>
<term>Plasmodium falciparum</term>
<term>Thailand</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Tropical medicine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Electrocardiographie</term>
<term>Artémisinine</term>
<term>Paludisme</term>
<term>Toxicité</term>
<term>Coeur</term>
<term>Evaluation</term>
<term>Traitement</term>
<term>Plasmodium falciparum</term>
<term>Médecine tropicale</term>
<term>Association médicamenteuse</term>
<term>Homme</term>
<term>Chimiothérapie</term>
<term>Thaïlande</term>
<term>Antiparasitaire</term>
<term>Antipaludique</term>
<term>Pipéraquine</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Thaïlande</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-9637</s0>
</fA01>
<fA02 i1="01"><s0>AJTHAB</s0>
</fA02>
<fA03 i2="1"><s0>Am. j. trop. med. hyg.</s0>
</fA03>
<fA05><s2>77</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MYTTON (Oliver T.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ASHLEY (Elizabeth A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PETO (Leon)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PRICE (Ric N.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LA (Yar)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HAE (Rae)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SINGHASIVANON (Pratap)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WHITE (Nicholas J.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>NOSTEN (Francois)</s1>
</fA11>
<fA14 i1="01"><s1>Shoklo Malaria Research Unit</s1>
<s2>Mae Sot</s2>
<s3>THA</s3>
</fA14>
<fA14 i1="02"><s1>Faculty of Tropical Medicine, Mahidol University</s1>
<s2>Bangkok</s2>
<s3>THA</s3>
</fA14>
<fA14 i1="03"><s1>Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road</s1>
<s2>Headington, Oxford</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="04"><s1>Menzies School of Health Research, Charles Darwin University</s1>
<s2>Darwin</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="05"><s1>Epicentre</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA20><s1>447-450</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6817</s2>
<s5>354000162434390080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0457237</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The American journal of tropical medicine and hygiene</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B05E02B4</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Electrocardiographie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Electrocardiography</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Electrocardiografía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Artémisinine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Artemisinin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Artemisinina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Paludisme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Malaria</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Paludismo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Coeur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Heart</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Corazón</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Plasmodium falciparum</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Plasmodium falciparum</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Plasmodium falciparum</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Médecine tropicale</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Tropical medicine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Medicina tropical</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Thaïlande</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Thailand</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tailandia</s0>
<s2>NG</s2>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antiparasitaire</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Parasiticide</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Antiparasitario</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Antipaludique</s0>
<s5>26</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antimalarial</s0>
<s5>26</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Antipalúdico</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Pipéraquine</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Piperaquine</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Piperaquina</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Protozoose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Protozoal disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Protozoosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Parasitose</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Parasitosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Parasitosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Electrodiagnostic</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Electrodiagnosis</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Electrodiagnóstico</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Quinoléine dérivé</s0>
<s2>FF</s2>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Quinoline derivatives</s0>
<s2>FF</s2>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Quinolina derivado</s0>
<s2>FF</s2>
<s5>38</s5>
</fC07>
<fN21><s1>302</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002732 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002732 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0457237
   |texte=   Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria

Short report : Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri